The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up
- 248 Downloads
We investigated the factors that predict chemotherapy-induced amenorrhea (CIA) and the prognostic significance of CIA after long-term follow-up.
We reviewed data from 241 premenopausal patients with breast cancer who underwent adjuvant CMF or FAC chemotherapy after breast cancer surgery between January 1995 and December 2000.
The median follow-up duration was 109.8 (range, 16.6–193.1) months. The age of CIA patients was older than non-CIA patients (median, 44 (range, 28–53) years and 36 (range, 25–49) years, respectively; P < 0.001). The addition of tamoxifen to the chemotherapy increased the incidence of CIA from 48% to 63.6% (P = 0.015). The 10-year disease-free survival (DFS) rate was higher in the CIA group compared with the non-CIA group in hormonal receptor-positive patients (78.4% vs. 67%, respectively; P = 0.022), and the 10-year overall survival (OS) rate also was higher in the CIA group compared with the non-CIA group (90.8% vs. 79.7%, respectively; P = 0.041).
The most important predictors of CIA are age and the addition of tamoxifen to the chemotherapy. CIA is likely to have an influence on DFS and OS in premenopausal patients with breast cancer with a positive hormone receptor, and it might be used as a surrogate marker for effective chemotherapy in these young Asian patients.
KeywordsBreast Cancer Overall Survival Tamoxifen Amenorrhea EXemestane
This work was supported by the Korea Science and Engineering Fund (KOSEF) grant funded by the Korea government (MOST) (R11-2000-082-03002-0).
- 5.Parulekar WR, Day AG, Ottaway JA, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study–NCIC CTG MA.5. J Clin Oncol. 2005;23:6002–8.CrossRefPubMedGoogle Scholar
- 7.Reis LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975–2004. Bethesda, MD: National Cancer Institute; 2007.Google Scholar
- 8.Han W, Ko S, Jeong J, Kim SI, Kim SW, Son BH, Ahn SH. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea––a report from the Korean Breast Cancer Society. J Clin Oncol. 2007;25:2360–8.CrossRefPubMedGoogle Scholar
- 9.Lee TH, Paik NS, Kim YK. Carcinoma of the breast in women 35 years of age or less. Cancer Res Treat. 1992;24:834–9.Google Scholar
- 24.Borde F, Chapelle-Marcillac I, Fumoleau P. Role of chemo-induced amenorrhea in premenopausal, node-positive, operable breast cancer patients: 9-year follow-up results of French Adjuvant Study Group (FASG) database. Breast Cancer Res Treat. 2003;82:30.Google Scholar
- 27.Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711–23.CrossRefPubMedGoogle Scholar